<DOC>
	<DOCNO>NCT00305409</DOCNO>
	<brief_summary>The purpose study determine whether administration synbiotic , comprised inulin bifidobacterial probiotic colonise gut wall down-regulate TNF-alpha pro-inflammatory cytokine mucosa Crohn 's patient active disease reduce mucosal inflammation induce remission .</brief_summary>
	<brief_title>Synbiotic Treatment Crohn 's Disease Patients</brief_title>
	<detailed_description>Crohn 's disease one two main form idiopathic inflammatory bowel disease . The Th1-mediated inflammatory response Crohn 's disease characterise increase IL-18 INF-gamma especially TNF-alpha , form lamina propria mononuclear cell . The aim investigation determine whether synbiotic comprise inulin bifidobacterial probiotic , previously show down-regulate TNF-alpha proinflammatory cytokine gut mucosa ulcerative colitis patient active disease , colonise bowel wall , reduce mucosal inflammation induce remission Crohn 's disease patient active disease , randomise control trial . Crohn 's disease associate high mortality incurs significant social , commercial NHS cost . Many patient refractile standard treatment , often undesirable side effect . An inexpensive , effective non-toxic treatment base synbiotic concept would contribute greatly relieve clinical financial burden disease .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Crohn 's disease large bowel ( +/ small bowel disease ) 1879 year old stable dos medication CDAI &gt; 150 , &lt; 450 short gut syndrome pregnancy lactation antibiotic therapy last 3 month probiotic therapy last 1 month &lt; 18 , &gt; 79 year old CDAI &lt; 150 &gt; 450 indeterminate colitis , ulcerative colitis alteration medication last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Crohn 's</keyword>
	<keyword>TNF-alpha</keyword>
	<keyword>Synbiotic</keyword>
	<keyword>Probiotic</keyword>
</DOC>